Interleukin 12/interleukin 23 pathway: Biological basis and therapeutic effect in patients with Crohn's disease

Table 1 Summary of randomized, placebo-controlled trials on ustekinumab in Crohn’s disease

Study (reference)	Publication year	Type of publication	Study design	Study phase
Sandborn et al[58]	2008	Full paper	Multicenter, double-blind, placebo-controlled, parallel cross-over	IIa
Sandborn et al[59] (CERTIFI)	2012	Full paper	Randomized, multicenter, double-blind, placebo-controlled	IIb induction
				IIb maintenance
Feagan et al[60] (UNITI-1)	2016	Full paper	Randomized, multicenter, double-blind, placebo-controlled	III
Feagan et al[60] (UNITI-2)	2016	Full paper	Randomized, multicenter, double-blind, placebo-controlled	III
Feagan et al[60] (IM-UNITI)	2016	Full paper	Randomized, multicenter, double-blind, placebo-controlled	Maintenance phase of UNITI 1 and 2 responders
Sandborn et al[63] (IM-UNITI long term extension)	2017	Abstract	Randomized, multicenter, double-blind, placebo-controlled	Maintenance phase of UNITI 1 and 2 responders
Sands et al[62] (UNITI-IM)	2018	Abstract	Randomized, multicenter, double-blind, placebo-controlled	Maintenance phase of UNITI 1 and 2 responders
Rutgeerts et al[61]	2018	Full paper	Randomized, multicenter, double-blind, placebo-controlled	Induction and maintenance of endoscopic healing